RU2560587C9 - Новые радиоиммуноконъюгаты и их применения - Google Patents

Новые радиоиммуноконъюгаты и их применения Download PDF

Info

Publication number
RU2560587C9
RU2560587C9 RU2012135430/10A RU2012135430A RU2560587C9 RU 2560587 C9 RU2560587 C9 RU 2560587C9 RU 2012135430/10 A RU2012135430/10 A RU 2012135430/10A RU 2012135430 A RU2012135430 A RU 2012135430A RU 2560587 C9 RU2560587 C9 RU 2560587C9
Authority
RU
Russia
Prior art keywords
antibody
cells
radioimmunoconjugate
antibodies
present
Prior art date
Application number
RU2012135430/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2560587C2 (ru
RU2012135430A (ru
Inventor
Рой Х. ЛАРСЕН
Йостейн ДАХЛЕ
Эювинд С. БРУЛАНД
Original Assignee
Нордик Нановектор Ас
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нордик Нановектор Ас filed Critical Нордик Нановектор Ас
Publication of RU2012135430A publication Critical patent/RU2012135430A/ru
Application granted granted Critical
Publication of RU2560587C2 publication Critical patent/RU2560587C2/ru
Publication of RU2560587C9 publication Critical patent/RU2560587C9/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2012135430/10A 2010-01-29 2011-01-28 Новые радиоиммуноконъюгаты и их применения RU2560587C9 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29952410P 2010-01-29 2010-01-29
NO20100143 2010-01-29
US61/299,524 2010-01-29
NO20100143A NO331080B1 (no) 2010-01-29 2010-01-29 Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav
PCT/EP2011/051231 WO2011092295A2 (en) 2010-01-29 2011-01-28 Novel radioimmunoconjugates and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2015127407A Division RU2664475C1 (ru) 2010-01-29 2011-01-28 Новые радиоиммуноконъюгаты и их применения

Publications (3)

Publication Number Publication Date
RU2012135430A RU2012135430A (ru) 2014-03-10
RU2560587C2 RU2560587C2 (ru) 2015-08-20
RU2560587C9 true RU2560587C9 (ru) 2015-11-27

Family

ID=44319900

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2012135430/10A RU2560587C9 (ru) 2010-01-29 2011-01-28 Новые радиоиммуноконъюгаты и их применения
RU2015127407A RU2664475C1 (ru) 2010-01-29 2011-01-28 Новые радиоиммуноконъюгаты и их применения

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2015127407A RU2664475C1 (ru) 2010-01-29 2011-01-28 Новые радиоиммуноконъюгаты и их применения

Country Status (25)

Country Link
US (2) US8628749B2 (enExample)
EP (2) EP2705857B1 (enExample)
JP (2) JP5646652B2 (enExample)
KR (2) KR101893720B1 (enExample)
CN (2) CN104338154B (enExample)
AU (1) AU2011209441B2 (enExample)
BR (1) BR112012018843B8 (enExample)
CA (1) CA2786655C (enExample)
DK (2) DK2705857T3 (enExample)
ES (2) ES2469140T3 (enExample)
HR (1) HRP20140538T1 (enExample)
IL (2) IL221091A (enExample)
MX (2) MX342539B (enExample)
NO (1) NO331080B1 (enExample)
NZ (1) NZ601055A (enExample)
PH (2) PH12012501516A1 (enExample)
PL (1) PL2528627T3 (enExample)
PT (1) PT2528627E (enExample)
RS (1) RS53346B (enExample)
RU (2) RU2560587C9 (enExample)
SG (1) SG182685A1 (enExample)
SI (1) SI2528627T1 (enExample)
UA (1) UA108631C2 (enExample)
WO (1) WO2011092295A2 (enExample)
ZA (1) ZA201205007B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1203372A1 (en) * 2011-12-13 2015-10-30 Nordic Nanovector Asa Chimeric therapeutic anti - cd37 antibodie hh1
US20150093397A1 (en) * 2012-03-30 2015-04-02 Immunogen, Inc. Methods for Increasing Efficacy of CD37-Based Therapy
CN103933575B (zh) * 2013-01-23 2017-09-29 上海新理念生物医药科技有限公司 一种三齿型连接子及其应用
EP3332813B1 (en) * 2013-06-07 2019-05-29 Nordic Nanovector ASA Combination therapy comprising anti-cd20 antibody and the radiolabeled hh1 monoclonal antibody
AU2014296219A1 (en) 2013-08-01 2016-02-25 Agensys, Inc. Antibody drug conjugates (ADC) that bind to CD37 proteins
BR112017020689A2 (en) * 2015-04-07 2018-06-26 Memorial Sloan-Kettering Cancer Center nanoparticulate immunoconjugates
GB201600328D0 (en) * 2016-01-08 2016-02-24 Univ Oslo Hf Anti-CD37 chimeric antigen receptors and immune cells expressing them
JP2019529433A (ja) * 2016-09-16 2019-10-17 ノルディック ナノベクター アルメン アクスイェ セルスカプ リロトマブおよび１７７Ｌｕ‐リロトマブ・サテトラキセタンを用いた非ホジキンリンパ腫の治療方法
KR102406510B1 (ko) 2017-07-03 2022-06-10 현대자동차주식회사 연료전지 시스템용 수소 공급 방법
CN109550061A (zh) * 2017-09-26 2019-04-02 南京江原安迪科正电子研究发展有限公司 一种用于放射性核素标记抗体的试剂盒及应用
US20210106703A1 (en) * 2017-11-22 2021-04-15 Nordic Nanovector Asa Radioimmunoconjugates in combination with other drugs as treatment against nhl
CA3137568A1 (en) * 2019-04-25 2020-10-29 Actinium Pharmaceuticals, Inc. Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseases
CN117241832A (zh) * 2021-03-19 2023-12-15 海德堡医药研究有限责任公司 B淋巴细胞特异性的鹅膏毒素抗体缀合物
WO2023057595A1 (en) 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1 rew
US20250333531A1 (en) 2021-10-06 2025-10-30 Nordic Nanovector Asa Humanized hh1
CN114081969A (zh) * 2021-11-23 2022-02-25 成都纽瑞特医疗科技股份有限公司 标记的小分子抗体、及其标记方法和应用
CN117285631A (zh) * 2023-11-24 2023-12-26 原子高科股份有限公司 用于放射性免疫治疗的Lu-177标记MUC1抗体

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
RU2335297C2 (ru) * 2002-12-31 2008-10-10 Иммуномедикс, Инк. Иммунотерапия злокачественных заболеваний в-клеток и аутоиммунных заболеваний с применением конъюгированных и неконъюгированных антител, комбинаций антител и слитых белков
WO2009019312A2 (en) * 2007-08-09 2009-02-12 Boehringer Ingelheim International Gmbh Anti cd37 antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
MXPA02010507A (es) * 2000-04-25 2003-05-14 Idec Pharma Corp Administracion intratecal de rituximab para el tratamiento de linfomas del sistema nervioso central.
RU2005122033A (ru) * 2002-12-13 2006-01-27 Митра Медикал Текнолоджи Аб (Se) Направленные противолимфомные средства с эффекторной и аффиновой функциями, связанные трехфункциональным реагентом
EP1587550B1 (en) * 2003-01-31 2011-07-27 Immunomedics, Inc. Methods and compositions for administering therapeutic and diagnostic agents
WO2005084179A2 (en) * 2003-12-01 2005-09-15 Immunomedics, Inc. Improved method for preparing conjugates of proteins and chelating agents
HUE026303T2 (hu) * 2005-07-25 2016-06-28 Emergent Product Dev Seattle B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
RU2335297C2 (ru) * 2002-12-31 2008-10-10 Иммуномедикс, Инк. Иммунотерапия злокачественных заболеваний в-клеток и аутоиммунных заболеваний с применением конъюгированных и неконъюгированных антител, комбинаций антител и слитых белков
WO2009019312A2 (en) * 2007-08-09 2009-02-12 Boehringer Ingelheim International Gmbh Anti cd37 antibodies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
E. SMELAND et al., Characterization of Two Murine Monoclonal Antibodies Reactive with Human B Cells, SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1985, vol. 21, pp.205-214. *
HENRIKSEN G. et al., Bi-labelled antibody and Bi-labelled streptavidin. Comparison of targeting efficacy of a lymphoma cell line in vitro, JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, 1997, vol. 39, no. 12, pp.1039-1046. *
MEREDITH R.F. et al., Intraperitoneal Radioimmunotherapy of Ovarian Cancer with Lutetium-177-CC49, The Journal of Nuclear Medicine, 1996, vol.37, no.9, pp.1491-1496. *

Also Published As

Publication number Publication date
HK1179157A1 (en) 2013-09-27
PH12017501038B1 (en) 2019-02-22
PL2528627T3 (pl) 2014-08-29
IL221091A0 (en) 2012-09-24
US9358309B2 (en) 2016-06-07
JP5855209B2 (ja) 2016-02-09
EP2705857A2 (en) 2014-03-12
PT2528627E (pt) 2014-06-12
HRP20140538T1 (hr) 2014-07-18
US20120301396A1 (en) 2012-11-29
KR101758409B1 (ko) 2017-07-14
RU2664475C1 (ru) 2018-08-17
SG182685A1 (en) 2012-08-30
CN102762230A (zh) 2012-10-31
PH12012501516A1 (en) 2024-04-03
EP2705857B1 (en) 2016-06-22
BR112012018843B8 (pt) 2020-12-22
JP2013518086A (ja) 2013-05-20
CA2786655A1 (en) 2011-08-04
BR112012018843B1 (pt) 2020-09-24
EP2528627B1 (en) 2014-03-19
KR101893720B1 (ko) 2018-08-30
NO331080B1 (no) 2011-09-26
SI2528627T1 (sl) 2014-08-29
KR20130028051A (ko) 2013-03-18
NZ601055A (en) 2013-12-20
RU2560587C2 (ru) 2015-08-20
US20140147384A1 (en) 2014-05-29
EP2528627A2 (en) 2012-12-05
JP2015057415A (ja) 2015-03-26
EP2705857A3 (en) 2014-07-30
BR112012018843A2 (pt) 2017-10-17
CA2786655C (en) 2016-12-13
ES2469140T3 (es) 2014-06-17
CN104338154A (zh) 2015-02-11
IL237507A0 (en) 2015-04-30
AU2011209441B2 (en) 2016-03-03
CN102762230B (zh) 2014-08-13
PH12017501038A1 (en) 2017-12-11
JP5646652B2 (ja) 2014-12-24
BR112012018843A8 (pt) 2017-12-19
IL221091A (en) 2015-03-31
CN104338154B (zh) 2017-09-22
RS53346B (sr) 2014-10-31
US8628749B2 (en) 2014-01-14
AU2011209441A1 (en) 2012-07-19
ES2592402T3 (es) 2016-11-30
MX2012008695A (es) 2012-11-23
WO2011092295A3 (en) 2011-11-24
DK2528627T3 (da) 2014-05-12
HK1195736A1 (en) 2014-11-21
DK2705857T3 (en) 2016-08-29
NO20100143A1 (no) 2011-08-01
MX342539B (es) 2016-10-04
RU2012135430A (ru) 2014-03-10
WO2011092295A2 (en) 2011-08-04
ZA201205007B (en) 2013-09-25
UA108631C2 (xx) 2015-05-25
KR20170084349A (ko) 2017-07-19

Similar Documents

Publication Publication Date Title
RU2560587C9 (ru) Новые радиоиммуноконъюгаты и их применения
US10646599B2 (en) Method for upregulating antigen expression
AU2015258801B2 (en) One-step labeling of antibodies to high specific activity with actinium-225
KR20240035757A (ko) 우로키나제 플라스미노겐 활성화제 수용체-표적화된 방사성 약제
HK1195736B (en) Radioimmunoconjugates and their use
HK1179157B (en) Radioimmunoconjugates and uses thereof

Legal Events

Date Code Title Description
TH4A Reissue of patent specification
TK4A Correction to the publication in the bulletin (patent)

Free format text: AMENDMENT TO CHAPTER -FG4A- IN JOURNAL: 23-2015 FOR TAG: (72)